Macomics is exploiting the potential of macrophage-based approaches to develop novel precision medicines to target disease specific macrophage biology. Macrophages (TAMs) are often the most abundant immune cell many types of cancer and modulating TAMs can enhance the body’s ability to fight cancer. Macomics will identify and characterise antibody candidates against the novel target of interest. Ono will have an exclusive option to license global rights to the candidates for further development and commercialization. Macomics will receive an up-front payment, R&D funding, and success-based milestone payments, as well as tiered royalties based on global net sales.
Read the full press release here.
